Psychedelics alter metaphysical beliefs
Using large prospective online samples and an independent controlled trial, the authors show that psychedelic use shifts metaphysical beliefs away from physicalist/materialist views and towards panpsychism and fatalism, with changes detectable up to six months. These shifts correlated with greater past use and improved mental-health outcomes, were moderated by baseline impressionability and mediated by perceived emotional synchrony during the experience, implying a causal influence of psychedelics on metaphysical belief.
Authors
- Fernando Rosas
- Robin Carhart-Harris
- Christopher Timmermann
Published
Abstract
Are psychedelics able to induce lasting changes in metaphysical beliefs? While it is popularly believed that they can, this has never been systematically tested. Here we exploited a large sample derived from prospective online surveying to determine whether and how beliefs concerning the nature of reality, consciousness, and free-will, change after psychedelic use. Results revealed significant shifts away from ‘physicalist’ or ‘materialist’ views, and towards panpsychism and fatalism, post use. These changes remained detectable at 6 months, and were associated with the extent of past use and improved mental-health outcomes. Path modelling suggested that the belief-shifts were moderated by impressionability at baseline and mediated by perceived emotional synchrony with others during the psychedelic experience. The observed belief-shifts post psychedelic use were confirmed by data from an independent controlled clinical trial. Together, these findings imply that psychedelic use has a causal influence on metaphysical beliefs – shifting them away from ‘hard materialism’.
Research Summary of 'Psychedelics alter metaphysical beliefs'
Introduction
Metaphysics concerns fundamental questions about reality, consciousness and free will, and people typically hold distinct metaphysical positions even if not explicitly aware of them. Timmermann and colleagues note that intense life events and altered states — including psychedelic experiences — can make such beliefs explicit, and that psychedelic experiences often include features (mystical-type experiences, perceived encounters with supernatural entities, feelings of unity or cosmic consciousness) that could plausibly induce durable shifts in metaphysical outlooks. Prior evidence for such shifts has been largely anecdotal, qualitative or retrospective, and no systematic, controlled quantitative study had tested whether psychedelics alter metaphysical beliefs. This study set out to address three linked questions: whether psychedelic use can causally affect core metaphysical beliefs about reality, consciousness and free will; whether any belief changes relate to mental-health outcomes; and what psychological mechanisms underlie the putative changes. To do so, the researchers conducted a prospective survey of people planning to attend psychedelic ceremonial retreats, measuring beliefs before and after use, and sought external validation by analysing data from an independent double-blind randomised clinical trial comparing psilocybin therapy with a 6-week course of escitalopram in patients with major depressive disorder.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Topics
- Authors
- APA Citation
Timmermann, C., Kettner, H., Letheby, C., Roseman, L., Rosas, F., & Carhart-Harris, R. (2021). Psychedelics alter metaphysical beliefs. https://doi.org/10.31234/osf.io/f6sjk
References (28)
Papers cited by this study that are also in Blossom
Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Davis, A. K., Clifton, J. M., Weaver, E. G. et al. · Journal of Psychopharmacology (2020)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Kometer, M., Pokorny, T., Seifritz, E. et al. · Psychopharmacology (2015)
Griffiths, R. R., Hurwitz, E. S., Davis, A. K. et al. · PLOS ONE (2019)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Forstmann, M., Yudkin, D. A., Prosser, A. M. B. et al. · PNAS (2020)
Richards, W. A., Rhead, J. C., Dileo, F. B. et al. · Journal of Psychedelic Drugs (2012)
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G. et al. · Psychopharmacology (2014)
Show all 28 referencesShow fewer
Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)
Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Forstmann, M., Sagioglou, C. · Journal of Psychopharmacology (2017)
Lyons, T., Carhart-Harris, R. L. · Journal of Psychopharmacology (2018)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Hartogsohn, I. · Journal of Psychopharmacology (2016)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Kirchner, K. · Journal of Psychopharmacology (2014)
Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)
Nutt, D. J., Carhart-Harris, R. L. · Current Drug Abuse Reviews (2015)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Cited By (44)
Papers in Blossom that reference this study
Dor-Ziderman, Y., David, J., Berkovich-Ohana, A. · Psychopharmacology (2025)
Zhou, K., De Wied, D., Carhart-Harris, R. L. et al. · PNAS (2025)
Evans, J., Aixalà, M., Anderson, B. T. et al. · Psychiatric Research & Clinical Practice (2025)
McGovern, H., Grimmer, H. J., Doss, M. K. et al. · Communications Psychology (2024)
Letheby, C. · Neuroethics (2024)
Moreton, S. G., Barr, N., Giese, K. J. · Death Studies (2024)
Nayak, S., Jackson, H., Griffiths, R. R. et al. · Journal of Psychoactive Drugs (2024)
Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)
Acevedo, E. C., Uhler, S., White, K. et al. · Journal of Psychoactive Drugs (2024)
Erritzoe, D., Timmermann, C., Godfrey, K. et al. · Nature Mental Health (2024)
Show all 44 papersShow fewer
Barba, T., Kettne, H., Radu, C. et al. · Scientific Reports (2024)
De Filippo, R., Schmitz, D. · Neuroscience and Biobehavioral Reviews (2024)
Peacock, C., Mascaro, J. S., Brauer, E. et al. · PLOS ONE (2024)
Argyri, E. K., Evans, J., Luke, D. et al. · SSRN (2024)
David, J., Bouso, J. C., Kohek, M. et al. · Frontiers in Psychiatry (2023)
Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)
Luan, L. X., Eckernäs, E., Ashton, M. et al. · Journal of Psychopharmacology (2023)
Lebedev, A. V., Acar, K., Horntvedt, O. et al. · Scientific Reports (2023)
Van Elk, M., Fried, E. I. · Therapeutic Advances in Psychopharmacology (2023)
Lawrence, D. W., Timmermann, C. · Journal of Psychoactive Drugs (2023)
Luke, D., Gandy, S., Irvine, A. et al. · Psychoactives (2023)
Sjöstedt-Hughes, P. · Frontiers in Psychology (2023)
Michael, P., Luke, D., Robinson, O. · Frontiers in Psychology (2023)
Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)
Carhart-Harris, R. L., Chandaria, S., Erritzoe, D. E. et al. · Neuropharmacology (2023)
Timmermann, C., Vollenweider, F. X. · Trends in Cognitive Sciences (2023)
Lutkajtis, A., Evans, J. · Journal of Psychedelic Studies (2023)
Rabinowitz, J., Lev-Ran, S., Gross, R. · Frontiers in Psychiatry (2023)
Peterson, A., Largent, E. A., Sisti, D. et al. · AJOB Neuroscience (2022)
Aqil, M., Roseman, L. · Neuropharmacology (2022)
Lerer, L. B., Varia, J. · Frontiers in Space Travel (2022)
Breeksema, J. J., Kuin, B. W., Kamphuis, J. et al. · Journal of Psychopharmacology (2022)
Watts, R., Kettner, H., Gandy, S. et al. · Psychopharmacology (2022)
Moreton, S. G., Burden-Hill, A., Menzies, R. E. · Clinical Psychologist (2022)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Hipólito, I., Mago, J., Rosas, F. E. et al. · Psyarxiv (2022)
Nayak, S., Singh, M., Yaden, D. B. et al. · Journal of Psychopharmacology (2022)
Yaden, D. B., Earp, D., Graziosi, M. et al. · Frontiers in Psychology (2022)
Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)
Orłowski, P., Ruban, A., Szczypiński, J. et al. · Journal of Psychopharmacology (2022)
Nayak, S., Griffiths, R. R. · Frontiers in Psychology (2022)
Timmermann, C., Watts, R., Dupuis, D. · Transcultural Psychiatry (2022)
Aday, J. S., Heifets, B. D., Pratscher, S. D. et al. · Psychopharmacology (2021)
Dupuis, D. · Frontiers in Psychology (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.